Paul Brittain, MD
Hematology & Oncology · Albuquerque, NMNPI 1184980989
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NM, where the typical reported total is $2,649.
Across 54 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$159
- Merck$108
- Gilead$96
- Bristol Myers Squibb$83
- AbbVie$82
- Johnson & Johnson$80
- plus $535 from 17 others
What the payments were for
- Food & beverage$1,08995%
- Education$555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $159 |
| Merck | 6 | $108 |
| Gilead(2 entities) | 5 | $96 |
| Bristol Myers Squibb | 3 | $83 |
| AbbVie | 4 | $82 |
| Johnson & Johnson | 3 | $80 |
| AstraZeneca | 2 | $65 |
| Sanofi | 3 | $60 |
| Novartis | 2 | $50 |
| Sun Pharmaceutical Industries Inc. | 1 | $42 |
| Bayer | 2 | $40 |
| Incyte Corporation | 1 | $29 |
| Springworks Therapeutics, Inc. | 2 | $29 |
| Tempus AI, Inc | 1 | $26 |
| Pfizer | 2 | $26 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| GSK | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
How this compares
$1,144 in reported general payments places this provider in the 35th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 21 | $398,601 |
| Lenalidomide | 19 | $272,447 |
| ImbruvicaIbrutinib | 14 | $265,222 |
| XtandiEnzalutamide | 14 | $218,587 |
| RevlimidLenalidomide | 12 | $184,934 |
| BrukinsaZanubrutinib | 16 | $137,229 |
| RubracaRucaparib Camsylate | 13 | $136,424 |
| EliquisApixaban | 102 | $99,844 |
| Abiraterone Acetate | 36 | $89,445 |
| XareltoRivaroxaban | 47 | $74,755 |
| Exemestane | 50 | $11,489 |
| Anastrozole | 274 | $8,608 |
| Tamoxifen Citrate | 46 | $2,061 |
| Bicalutamide | 41 | $1,177 |
| Letrozole | 59 | $1,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $26 | $498,444123 claims |
| Astellas Pharma US IncXtandi | $19 | $218,58714 claims |
| Bristol Myers SquibbRevlimid | $83 | $184,93412 claims |
| Johnson & JohnsonXarelto | $80 | $74,75547 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 54 hematology & oncology providers in New Mexico.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Scott HerbertAlbuquerque$14K
- Jose AvitiaAlbuquerque$11K
- Zoneddy DayaoAlbuquerque$10K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.